The GNS Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the GNS gene in the NCI-H1975 human lung adenocarcinoma epithelial cell line. This heterogeneous loss-of-function model abrogates glucosamine (N-acetyl)-6-sulfatase activity, the lysosomal enzyme responsible for hydrolyzing 6-sulfate groups from N-acetyl-D-glucosamine residues of heparan sulfate and keratan sulfate. By targeting GNS, researchers can investigate the consequences of impaired sulfated glycosaminoglycan degradation within a tumorigenic epithelial context, enabling functional dissection of lysosomal metabolism and its interplay with oncogenic signaling. The polyclonal format provides a robust, population-level knockout system suitable for biochemical, cell biological, and pharmacological studies without the clonal artifacts associated with single-cell-derived lines.
The host NCI-H1975 cell line is derived from a pleural effusion of a female patient with non-small cell lung adenocarcinoma and harbors activating EGFR mutations L858R and T790M. These mutations drive constitutive tyrosine kinase signaling and are commonly observed in clinical resistance to first-generation EGFR inhibitors, rendering NCI-H1975 a well-established model for EGFR-mutant lung cancer. As adherent epithelial cells, they retain the morphological and proliferative characteristics of the original tumor, making them suitable for studying tumor cell biology, drug response, and metastasis. The GNS knockout in this background offers a unique platform to examine how lysosomal dysfunction, induced by glycosaminoglycan accumulation, intersects with EGFR-driven oncogenic pathways.
GNS encodes glucosamine-6-sulfatase, a member of the sulfatase family that requires post-translational modification by sulfatase-modifying factor 1 (SUMF1) for catalytic activity. The enzyme functions within the glycosaminoglycan degradation pathway, acting downstream of heparanase and iduronate-2-sulfatase and alongside alpha-L-iduronidase and N-acetylglucosaminidase to sequentially break down heparan sulfate chains. GNS knockout abolishes this activity, leading to lysosomal accumulation of sulfated glycosaminoglycans and potentially disrupting downstream signaling mediated by heparan sulfate, which regulates growth factors, cytokines, and morphogens. Transcription factors TFEB, TFE3, and MITF, master regulators of lysosomal biogenesis and autophagy, may be activated in response to lysosomal stress, while altered heparan sulfate sulfation patterns can impact receptor tyrosine kinase signaling and cell adhesion. The GNS protein interacts with SUMF1 and other sulfatase family members, placing it within a tightly coordinated network critical for maintaining cellular glycosaminoglycan homeostasis.
In EGFR-mutant lung adenocarcinoma cells, lysosomal function is frequently reprogrammed to support tumor metabolism, enhance growth factor recycling, and promote drug resistance. GNS loss impairs normal heparan sulfate catabolism, which can modulate the extracellular matrix, tumor-microenvironment interactions, and signaling cascades mediated by EGFR and other receptors. The accumulation of sulfated glycosaminoglycans may alter cell proliferation, migration, and invasion, phenotypes readily assayed in the NCI-H1975 background. This model thus enables the investigation of how glycosaminoglycan storage disorders, such as mucopolysaccharidosis type IIID, mechanistically intersect with cancer biology, potentially revealing novel therapeutic targets or biomarkers. The EGFR-mutant context is particularly valuable for understanding metabolic vulnerabilities that arise from lysosomal dysfunction in adenocarcinoma.
The GNS Knockout NCI-H1975 Polyclonal Cells support a broad range of research applications, including studies of lysosomal storage disorders, glycosaminoglycan metabolism in cancer, and the role of heparan sulfate in the tumor microenvironment. They are suited for drug screening for Sanfilippo syndrome, employing sulfatase activity assays, Alcian blue staining for glycosaminoglycan accumulation, immunofluorescence detection of lysosomal markers (e.g., LAMP1), and LC-MS-based heparan sulfate profiling. Additional applications include lysosomal pH measurement, cell proliferation and migration/invasion assays, and transcriptomic or proteomic analyses of TFEB/TFE3/MITF-regulated pathways. For further information or technical support, please contact Ascent Research.
